The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 06, 2024
Filed:
Dec. 21, 2021
Applicant:
Amgen Inc., Thousand Oaks, CA (US);
Inventors:
Neeraj Jagdish Agrawal, Natick, MA (US);
Kevin Graham, Thousand Oaks, CA (US);
Agnes Eva Hamburger, Newbury Park, CA (US);
Christopher Mohr, Newbury Park, CA (US);
Derek E. Piper, Santa Clara, CA (US);
Kenneth William Walker, Newbury Park, CA (US);
Zhulun Wang, Los Altos, CA (US);
Cen Xu, Newbury Park, CA (US);
Assignee:
AMGEN INC., Thousand Oaks, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); C12P 21/08 (2006.01); G01N 33/53 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); A61P 25/06 (2006.01); A61K 38/22 (2006.01); A61K 47/68 (2017.01); A61K 38/17 (2006.01); A61K 51/10 (2006.01); C07K 14/575 (2006.01); C07K 16/26 (2006.01); C07K 14/72 (2006.01); C07K 14/47 (2006.01); G01N 33/74 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 38/2278 (2013.01); A61P 25/06 (2018.01); C07K 16/2869 (2013.01); A61K 38/1796 (2013.01); A61K 38/22 (2013.01); A61K 47/6843 (2017.08); A61K 47/6849 (2017.08); A61K 51/10 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2300/00 (2013.01); C07K 14/47 (2013.01); C07K 14/575 (2013.01); C07K 14/57563 (2013.01); C07K 14/72 (2013.01); C07K 16/00 (2013.01); C07K 16/26 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/70 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C12N 2501/30 (2013.01); G01N 33/6854 (2013.01); G01N 33/6896 (2013.01); G01N 33/74 (2013.01); G01N 2333/575 (2013.01); G01N 2333/5757 (2013.01); Y02A 50/30 (2018.01);
Abstract
The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.